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(structural and nonstructural RV proteins,
respectively). This implies that like the simian
RV, Wa replication is also affected by both A1
and A3. Additionally, tunable resistive pulse
sensing technology (TRPS) measured changes in
the population distribution of released
nanoparticles between 60-140 nanometers.
Additionally, TEM morphometric analyses
showed ultrastructural changed in RV-infected
cells treated with A1 or A3.
This included
nucleus to cytoplasm ratios that were determined
by TEM and whole cell fluorescent assays that
disclosed significant nuclear size alterations with
the addition of RV which implied modifications of
the apoptosis and autophagy pathways.
Moreover, the increased presence of autophagic
vesicles seen with RV+A1 reinforced the model of
a switch from the apoptosis to the autophagy
pathway. In addition, immunoblot assays reveal
the presence of cannabinoid 1 and 2 receptors on
MA104 cells. These receptors bind A1 and A3
and are important in signaling in the
endocannabinoid system. This implies a role for

ABSTRACT
Rotavirus (RV) causes severe lifethreatening diarrhea in young children and
immunocompromised individuals. There are
several licensed attenuated vaccines for young
children, but there are no vaccines or antiviral
therapeutics for immunocompromised patients of
any age.
Previously, our laboratory
demonstrated that arachidin 1 (A1) and arachidin
3 (A3) decreases the number of infectious simian
RV particles and RV non-structural protein 4
(NSP4) in a human intestinal cell line which
suggests effects on RV replication. This study
examined the effects of the arachidins on the
human RV (Wa)-infected African green monkey
kidney cell line, MA104. The addition of either A1
or A3 did not decrease the viability of MA104
cells, however plaque forming assays measured
significant decreases in the number of infectious
RV particles with the addition of the arachidins.
Correspondingly, western blot analyses revealed
a change in the presence of VP6 and NSP4
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A1 and A3 in modulating cannabinoid receptor
cell signaling in RV-infected cells which indicates
a mechanism of action of A1 and A3 with
potential RV therapeutic activity.

prevention of RV disease, especially in
immunocompromised individuals. Likewise, the
discovery of the antiviral mechanism(s) could lead to
the development of compounds with a broad range of
antiviral activity.

INTRODUCTION

Our laboratory is investigating the effects of
highly purified stilbenoids extracted from peanut
(Arachis hypogea) hairy root cultures on RV
infections (Ball et al., 2015). Stilbenoids are
secondary metabolites derived from plants that have
antioxidant, anticancer, antifungal and antiinflammatory properties, and have shown many
potential human health benefits (Aggarwal et al.,
2004; Athar et al., 2007; Roupe et al., 2006; Yang et
al., 2017). They are products of the
phenylpropanoid/acetate pathway and act as
phytoalexins produced by plants such as grapes,
berries, and peanuts in response to pathogens (Huang
et al., 2010; Moss et al., 2013). Two prenylated
stilbenoids, arachidin 1 (A1) and arachidin 3 (A3),
significantly inhibit the production of infectious
simian RV (SA114f) and show a reduction in the
viral nonstructural protein, NSP4, which is critical
for viral replication (Ball, et al., 2015). Other studies
have demonstrated that the activation of cellular
signaling pathways is dependent on the RV strains
and cell lines used in their experiments (Di Fiore et
al., 2015; Halasz et al., 2010; Holloway et al., 2009;
Holloway and Coulson, 2006; Otto et al., 2015;
Saxena et al., 2016; Uzri and Greenberg, 2013).
This study shows significant changes in the
number of infectious human RV (Wa) particles
produced with the addition of either A1 or A3 on the
African green monkey kidney cell line, MA104.
Correspondingly, western blot assays show changes
in the presence of both structural and nonstructural
RV proteins, VP6 and NSP4, respectively,
suggesting an effect on progeny RV particles and
replication. Additionally, tunable resistive pulse
sensing technology (TRPS) using the qNano system
by Izon revealed different patterns in the size

Rotaviruses (RV) are members of the Reoviridae
family that causes infantile gastroenteritis in children
less than 5 years of age (Ward, 1996), and severe
diseases in pediatric and adult immunocompromised
individuals (Anderson & Weber, 2004; Bakare et al.,
2010; Park et al., 2015; Patel et al., 2010; Yin,
Metselaar, Sprengers, Peppelenbosch, & Pan, 2015).
There are two licensed RV attenuated vaccines,
RotaTeq®
(Merck)
and
Rotarix®
(GlaxoSmithKline), in the United States that prevent
severe diarrhea (Leshem et al., 2014; Yen et al.,
2014), and an attenuated RV vaccine, Rotavac®, in
India (Bhandari et al., 2014). However, the vaccines
efficacies are dependent on the timing of vaccination,
and are designed to protect against common RV
strains (Jiang et al., 2010; Patton, 2012). Their
efficacies are dependent on the genetic stability of
the attenuated virus vaccines strains (Patton, 2012),
but RV reassortments between RV strains are
common and result in new infectious RV strains
(Patton, 2012; Weinberg et al., 2013). This could
produce RV strains that are not affected by the
vaccine strains. Furthermore, the vaccines are
contraindicated for immunosuppressed individuals,
and there are no antiviral therapeutic agents currently
available for RV infections. Besides the possibility
of contracting RV-induced diarrhea directly from the
infected individuals, there are documented cases of
horizontal transmission of vaccine RV among
immunocompromised household contacts from
vaccinated children who shed the vaccine virus
(Hsieh et al., 2014; Patel et al., 2010; Yen et al.,
2015). Development of effective antiviral drugs that
affect a wide-range of RV strains and reduces the
burden of disease is an important strategy for the
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(CD) (Cavasol® W7M) (Yang et al., 2015). A 72hour treatment of 9 g/L CD was selected based on the
highest production of A1. At day nine of the hairy
root culture, the spent medium from each flask was
removed and replaced with elicitation medium (fresh
MSV medium with 9 g/L methyl-β-CD and
incubated in the dark at 28oC for an additional 72 h
to induce synthesis and secretion of stilbenoids into
the culture medium as recently described (Yang et
al., 2015). After the elicitation period, the culture
medium was removed from each flask and combined.
This pooled medium was mixed with an equal
volume of ethyl acetate in a separatory funnel to
extract the stilbenoids as described previously
(Condori et al., 2010). The ethyl acetate phase was
recovered and was dried in a rotavapor (Buchi), and
A1 and A3 were purified from the extract by HPCCC
as follows. The dried ethyl acetate extract was
suspended in HPCCC solvent system (hexane: ethyl
acetate: methanol: water [4:5:3:3]) and injected into
a SpectrumTM (Dynamic Extractions) HPCCC
system. HPCCC fractions containing A1 and A3
with over 95% purity based on HPLC analysis (UV
340 nm) were combined, dried under a nitrogen
stream and used for viral assays (Ball et al., 2015).
As previously demonstrated, A1 and A3 were the
major stilbenoids present in the culture medium, and
the dry mass of each stilbenoid was reconstituted in
0.02% DMSO in MEM medium (Ball et al., 2015).

distribution of nanoparticles released from the
arachidin treated, RV-infected MA104 cells.
Transmission electron microscopy (TEM) was used
to observe morphometric changes between the RVinfected arachidin-treated cells, and the changes
observed in the ratios of the nucleus to cytoplasm
were substantiated with fluorescent-labeled whole
cell assays.
It is known that A1 and A3 bind to cannabinoid
receptors which are important in the control of the
endocannabinoid system. In this study, we revealed
the presence of cannabinoid receptors 1 and 2 on
MA104 cells. This implies a role for A1 and A3 in
modulating cannabinoid receptor cell signaling in
RV-infected cells suggesting a mechanism of action
of A1 and A3 with potential RV therapeutic activity
MATERIALS AND METHODS
Cell lines and virus. MA104 cells were obtained
from ATCC (Rockville, MD) and maintained in
Eagle Modified Essential Medium (MEM; Gibco,
Grand Island, NY) supplemented with 5% fetal
bovine serum (FBS), glutamine (2 mM), penicillinstreptomycin (100 µg/mL) and non-essential amino
acids (Sigma, St. Louis, MO as a 100X solution. The
amino acids were used at a 1X concentration of 100
µM each.) (Mitchell and Ball, 2004). The cell line
was confirmed to be free of mycoplasma
contamination using the MycoFind mycoplasma
PCR kit version 2.0 (Clongen Laboratories, LLC).
RV Wa (G[1] P[8] genotype) was amplified
(Matthijnssens et al., 2008). Viral titers on virus
stocks were determined in MA104 cells, followed by
storage at -80°C. Arachidin 1 and 3 efficacies
against RV were tested using MA104 cells.

Viability Assay. Viability assays were performed as
previously described using the Trypan blue cell
exclusion assays (Ball et al., 2015; Freshney, 1994).
MA104 cells were grown to 80% confluence in 6well tissue culture plates (Corning Life Sciences) and
starved for fetal bovine sera 12 hours prior to the
addition of RV alone, DMSO alone, RV + DMSO,
RV + 20 µM A1, RV + 20 µM A3, 20 µM A3, 20
µM A1 and NV (no virus). At 18 hours post infection
(hpi) a suspension of 106 cells/ml was diluted 1:1
with a 0.4% Trypan blue solution and loaded onto a
hemocytometer. The number of stained cells and

Bioproduction of stilbenoids in hairy root cultures of
peanut. Stilbenoids were produced as previously
reported using the established hairy root line 3 from
peanut cv. Hull (Condori et al., 2010) that was
stimulated with the elicitor methyl-β-cyclodextrin

3

total number of cells were counted, and the
calculated percentage of unstained cells was reported
as the percentage of viable cells. Each treatment was
performed in triplicate, and data was expressed as the
mean +/-standard deviation (SD). Comparisons were
statistically evaluated by a one-way analysis of
variance (ANOVA) and Student’s t two tailed tests
using Excel (significance level, p ≤ 0.05).

2015). Briefly, ten-fold dilutions of RV alone and
RV with 0.002% DMSO and 20 µM A1 or A3 were
added to the serum starved MA104 cells for one hour
as described above. The virus inoculum was replaced
with 3 mL of a medium overlay (1:1 mixture of 1.2%
agarose [Apex Low Melting Point Agarose, Genesee
Scientific Inc] and complete MEM containing 0.5
µg/mL trypsin and incubated at 37°C in 5% CO2 for
3 to 4 days or until plaques became visible. A neutral
red overlay (1:1 mixture of 1.2% agarose with an
equal volume of serum-free MEM containing 50
µg/mL neutral red) was prepared and 2 mL per well
of stain overlay was added on top of the first
agarose/medium overlay. The six-well plates were
incubated at 37°C until plaques were visible
(approximately 12 to 72 h). The individual plaques
were counted, and the titers were calculated as
follows: Number of plaques x 1/dilution factor x 1/
(mL of inoculum) = PFU/mL. Plaque forming assays
were performed in triplicate with data are expressed
as mean +/-SD. Comparisons were statistically
evaluated by analysis of variance (ANOVA) and
Student’s t two tailed tests using Microsoft Excel
2011 software (significance level, p ≤ 0.05).

RV Infections. To test the biological activity of the
stilbenoids on RV infections, MA104 cells were
grown to 80% confluence in 6 well tissue culture
plates (Corning Life Sciences), starved for fetal
bovine sera twelve hours prior to infection and then
infected with RV (Wa) as previously described
(Arnold et al., 2009; Ball et al., 2015; Yakshe et al.,
2015). Rotavirus (Wa) stocks were sonicated for five
minutes using a cup horn attachment with a Q500
Sonicator (QSonica Sonicators, Newtown, CT), and
incubated in serum-free MEM with 1 µg/mL trypsin
(Worthington Biochemical, Lakewood, NJ) for 30
min at 37°C. The activated viral inoculum was
incubated with cells for 1 h at 37°C in 5% CO2 at
multiplicity of infection (MOI) of 2. The inoculum
was replaced with serum-free MEM supplemented
with 1 µg/mL trypsin and incubated for 18 hpi. The
supernatants were collected, clarified at 300 x g for 5
min, and stored at -80°C for plaque assays and TRPS
analysis (see below). The cells were washed in cold
1X Dulbecco's PBS (Caisson Laboratories,
Smithfield, UT), and released from the plates using a
0.25%
Trypsin-EDTA
Solution
(Caisson
Laboratories, Smithfield, UT). After the addition of
MEM with 5% FBS, the cells were suspended in cold
1X PBS and dilutions were prepared for live/dead
cell counts (see above in Viability Assays). For TEM
analysis, approximately 2 x 106 cells were washed in
cold 1X PBS, fixed with 5% glutaraldehyde and used
for TEM analysis as described below.
Infectious RV quantification. PFU assays were
performed in triplicate as previously described
(Arnold et al., 2009; Ball et al., 2015; Yakshe et al.,

Quantification and Size Distribution of RV Particles.
To determine the concentration and size of
nanoparticles released from the treated samples (RV,
RV+A1 and RV+A3), TRPS analysis using the
qNano system (Izon Science, Cambridge, MA) was
employed. TRPS is based on a coulter counter that
is composed of two fluid reservoirs filled with an
electrolyte or other conductive media and separated
by a membrane containing a pore (Kozak et al., 2011;
Weatherall et al., 2016). When an electrical field is
applied across the pore, the resistance to the resulting
ionic current is indirectly proportional to the crosssectional area of the pore. When a non-conducting
particle passes through the pore, the increase in
resistance is proportional to the particle volume
relative to pore size. This change in resistance is
detected as a pulse in an ionic current. The pulse
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examined with a Hitachi H-7000 electron
microscope operating at 75 KeV. Negatives were
digitized at 1200 dpi and analyzed using
Macnification Version 2 (Orbicule, Inc.,
www.orbicule.com). RV particles were observed in
RV-infected cells, and the average diameters of
enveloped and non-enveloped particles were
measured (n=23 particles for each group; the data
was expressed and graphed as the mean +/- SD. Also,
the mean the cell nucleus to cytoplasm ratios were
determined using twelve micrographs of six
treatment groups (No virus, RV, RV+A1, RV+A3,
A1, A3). All data were presented as the mean ±
standard deviation. Statistical analyses were
performed using one-way analysis of variance
followed by Bonferroni's post hoc test using Excel.
P<0.05 was considered to indicate a statistically
significant difference.

frequency is proportional to particle flow rate and
particle concentration (DeBlois and Bean, 1970).
This system provides a quick and accurate way to
measure individual sizes of nanoparticles and their
volume in a solution (Farkas et al., 2013; Vogel et
al., 2011). All qNano experiments were performed
using the manufacturer's established protocols (Bo et
al., 2014; Jones, 2015; Vogel et al., 2011). Prior to
counting and measuring the particles, samples were
purified using a qEV size exclusion column from
Izon that contains a resin with an approximately 75
nm pore size. The purified particles samples were
suspended in PBS with 0.025% Tween 20 to reduce
particle aggregation and ease the wetting of the
nanopore. Dilutions of 1:1000 of the samples were
placed on the qNano size-tunable nanopore (NP100,
Izon), and each sample was measured as a transient
change in the ionic current flow. This was denoted as
a blockade event with its amplitude representing the
blockade magnitude.
Because the blockade
magnitude is proportional to the particle size,
accurate particle sizing was achieved after
calibration with 100 nm particles (CPC100B, Izon)
using identical settings. The size distribution and
concentration analyses were performed using IZON
Science proprietary software v3.2.2.268.

W1Xhole cell fluorescent labelling of nucleus and
plasma membranes. The nucleus and plasma
membranes of MA104 cells were fluorescently
labelled to determine the ratios of the nucleus to
cytoplasm of whole cells to compare to the nucleus
to cytoplasm ratios obtained with TEM. Briefly,
MA104 cells were grown to 80% confluence in 8well slides (Lab-Tek Chamber Slide System, Nunc,
Inc. Naperville, IL) and RV-infected and treated with
the arachidins as described above (RV alone, RV
with 20 µM A3 or A3, 20 µM A1 alone, or 20 µM
A3 alone, and cells without treatments (NV-no
virus). At 18 hpi, the cells were washed with 1X PBS
one time at 25°C, and then fixed with 1%
Glutaraldehyde (Electron Microscopy Science,
Hatfield, PA) for one hour at 25°C in a fume hood
(Harlow and Lane, 1988). Following fixation, the
cells were washed twice with 1X PBS at 25°C. The
Image-IT™ LIVE Plasma Membrane and Nuclear
Labeling Kit (I34406) (Molecular Probes, Invitrogen
detection Technologies, Eugene, OR) was used to
label the cells. Briefly, one solution for the single
step staining for both stains was prepared by adding

Morphometric analysis of RV-infected MA104 cells.
TEM analysis was performed on RV-infected
MA104 cells to visualize the effects of the A1 and
A3 on progeny virus and cellular morphology.
Samples were prepared as described (Wright, 2000).
RV-infected MA104 cells with and without 20 µM
A1 or A3 were incubated for 18 hpi, washed with
PBS and then trypsinized. Cells were pelleted and
fixed with 5% glutaraldehyde overnight at 4°C. The
cells were post-fixed with 2% osmium tetroxide,
dehydrated with a graded ethanol series (15 - 30
minutes incubation of the following: 30%, 50%,
70%, 80%, 90%, and 100% ethanol), infiltrated and
embedded in Spurr’s resin. Thin sections were
stained with uranyl acetate and lead citrate and were
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5.0 µg/mL Alexa Flour 594-labeled wheat germ
agglutinin and 1 µM Hoechst 33342 stain into 1X
PBS. One-hundred µLs of the labelling solution was
added to each well in 8-well chambered slides, and
incubated for ten minutes at 25ºC, removed and the
cells were washed twice with 1X PBS, and mounted
in 1X PBS. The microscopic analysis was carried out
using the Olympus BX50 with DP Manager System
compound light microscope with epifluorescence
illumination for Alexa Fluor 594 labeled wheat germ
(Excitation 480-550nm, dichroic mirror DM 570nm,
barrier filter 590nm) and Hoechst 33342 (Excitation
330-385nm, dichroic mirror DM 400nm, barrier
filter BA420nm) with the DP71 camera (Olympus
Corporation, Shinjuku, Tokyo, Japan) equipped with
x 40 and X100 objectives. The images were digitized
using the DP Controller software (Olympus
Corporation), and the pixels of the nucleus and whole
cell were measured using Macnification Version 2
(Orbicule, Inc., www.orbicule.com). Excel was used
to determine the nucleus to cytoplasm ratio of the
cells of 45 to 56 cells per treatment. Data are
presented as the mean ± standard deviation.
Statistical analyses were performed using one-way
analysis of variance followed by Bonferroni's post
hoc test using Microsoft Office Excel 2016 software.
P<0.05 was considered to indicate a statistically
significant difference.

Protein Biology Products ProSignal Femto ECL
Reagent (Genesee Scientific). The digital images
were captured using the Amersham Imager 600 (GE
Healthcare UK Limited Amersham Place Little
Chalfont Buckinghamshire HP7 9NA United
Kingdom). The expression of GAPDH was used as a
loading control on all western blots. Rabbit antiGAPDH (PA1-988, Thermo Fisher Scientific,
Waltham, MA) was incubated at a 1: 5000 dilution
(0.2ng/µl) and visualized for the viral proteins, VP6
and NSP4, as described above for GAPDH.
Cell lysates were prepared from treated and
untreated MA104 cells, and total protein was
quantified using a micro-BCA protein assay as
previously described (Ball et al., 2015). For
immunoblot assays, two-fold dilutions of RVinfected and noninfected MA104 cell lysates (10, 5,
2.5, 1.25 µg) were added to nitrocellulose
membranes using a slot blot apparatus (Bio-Rad).
Membranes were blocked with 10% nonfat dry milk
and probed with a 1 µg/mL of rabbit anti-CNR1/2
antibodies from Assay Biotechnology (Sunnyvale,
CA), and incubated with 8 ng/mL of goat anti-rabbit
IgG (H&L) Alexa Fluor 546 (Invitrogen, Carlsbad,
CA). Goat anti-rabbit Alexa Fluor®546-labelled
antibodies (Life Technologies) were added and
reactive bands were visualized using the 556 nm
excitation laser and 573 nm emission filter on the
Typhoon 9500 Plus laser scanner (GE Life Sciences,
Marlborough, MA).

Western blot and Immunoblot assays. For western
blot analyses of RV proteins, 20 µg (to detect VP6)
and 1 µg (to detect NSP4) of cell lysates were
prepared and quantified as described above,
separated by 12% SDS-PAGE, and electroblotted
onto nitrocellulose membranes. The membranes
were probed with a 1:1000 dilution of polyclonal
rabbit serum anti-NSP4 (150-175) or polyclonal
rabbit anti-VP6 specific antibodies (a gift from Dr.
Judith M Ball), and reactive bands were visualized
by the addition of 1: 5000 dilution (0.2ng/µl) HRPconjugated donkey anti-rabbit IgG (GE Health
Sciences) with the addition of the Prometheus

RESULTS
Viability of RV-infected MA104 cells in the presence
of DMSO, A1, and A3.
At 18 hpi, RV-infected cells showed an average
viability of 89.46% (STD dev ± 5.6) and
RV+0.002% DMSO showed 91.5% (STD dev ± 5.2)
cell viability. Cells treated with RV+20 µM A1
displayed a viability of 90% (std dev ± 0.6) and 20
µM A1 alone had a 91.3% (std dev ± 2.6) viability.
Cells treated with RV + 20 µM A3 displayed a
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of 7.11E9 (Figure 2). This demonstrates a 59-fold
and 55-fold reduction in PFU/ml in RV+A3 and
RV+A1, respectively resulting in P = 1.356E-07 for
both arachidins when compared to RV. Both
RV+A3 and RV+A1 showed no statistical difference
from each other (P = 0.3731).

viability of 92.5% (std dev ± 2.6) and 20 µM A3
alone had a 95.8% (std dev ± 2.6) viability. Untreated
cells (no virus - NV) demonstrated 93% (std dev ±
2.6, and NV+0.002% DMSO showed a viability of
97.5% (std dev ±0.58). There were no statistical
differences between all treatments except RV+A1
was statistically different from A3 (P = 1.11E-4) and
NV+0.002% DMSO (P = 1.31E-5) (Figure 1).

Figure 1. MA104 cell viability assay. Trypan blue exclusion
assays were performed in triplicate (RV, RV+0.002% DMSO,
RV 20µM A1, 20µM A1, RV+20 µM A3, 20 µM A3, NV-no
virus and NV+0.002% DMSO) at 18 hpi. The mean percent
live/dead cells were calculated. Data were expressed as the
mean ± SD, and comparisons were statistically evaluated with
a one-way ANOVA and two-tailed Students’ 𝑡-tests followed
by Bonferroni’s correction using Microsoft 2016 Excel
software (significance level, P <0.05). *Statistically different
(RV+A1/A3) with P = 1.11E-4. **Statistically different
(RV+A1/NV+0.002% DMSO) with P = 1.31E-5.

Figure 2. Plaque forming assays using supernatants from
RV-infected and arachidin treated MA104 cells. MA104
cells were infected with Wa RV (Wa) at an MOI of 2 and treated
with 20 µM A1 or A3. At 18hpi, the cell supernatants were
collected, centrifuged, and serial diluted for plaque forming
assays to determine the number of infectious viral particles/mL
as plaque forming units (PFU/ml). Comparison of RV to
RV+A1 and RV to RV+A3 both P = 1.356E-7.

TEM viral particle size analyses of rv-infected
ma104 cells.
The presence of enveloped and nonenveloped RV
particles was demonstrated in micrographs with a
scale bar of 0.25 microns, and the less mature
enveloped RV particle was shown entering the ER
from a viroplasm (Figure 3A). The average
diameters of enveloped and non-enveloped RV
particles were measured (n=20 particles for each
group) (Figure 3B). The less mature enveloped RV
particles had a mean diameter of 112.736 ±3.20 and
the more mature nonenveloped RV particles had a

The effects of A1 and A3 on the production of
infectious RV particles.
Supernatants were collected at 18 hpi from the RVinfected and RV-infected with 20 µM A1 or A3 and
used for plaque forming assays to quantify infectious
RV particles. Plaques were counted and the average
of three experiments was calculated and graphed as
PFU/mL (Figure 2). The PFU assays demonstrated a
statistical difference in the production and release of
infectious viral particles with the addition of A1 and
A3. At 18 hpi, RV only had a titer of 3.9E11,
RV+A3 had a titer of 6.67E9, and RV+A1 had a titer
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mean diameter of 72.391 ± 2.172 nanometers which
were statistically significant P = 1.2366E-34 (Figure
3B).

many small mitochondria-like organelles and many
vesicles in the cytoplasm (Figures 4E and F).
TEM analyses of MA104 cell nucleus to cytoplasm
ratios. The ratio of nucleus to cytoplasm was
calculated using twelve representative cells from
each treatment. At 18 hpi, the mean ratios of the
control cells treated with A1 (0.44±0.218) and A3
(0.39±0.177) were like the cells with no treatment,
NV (0.48±0.173) (Figure 5), while the RV-infected
cells demonstrated an increased nucleus to
cytoplasm ratio with a mean ratio of 1.31±0.347.
RV-infected cells treated with A3 and A1 had mean
ratios, 0.49±0.184 and 0.54±0.156, respectively,
which were comparable to the ratios of the control
cells. However, both arachidin, treated RV-infected
cells displayed different ultrastructure characteristics
than the control cells. RV-infected cells treated with
A1 had many autophagosomes and large sized
mitochondria, while the A3 treated cells exhibited
many small mitochondria and many vesicles in the
cytoplasm (Figure. 5).

Figure 3. Transmission electron micrograph (TEM) of Wa
rotavirus infected MA104 cells at 18hpi. Final Magnification
= 57,000x. A) Endoplasmic reticulum (ER), Viroplasm (V),
Enveloped virus particles (E), and non-enveloped virus particle
(NE). B) Measurements of RV particles in TEM micrographs
of MA104 cells infected with Wa rotavirus at 18 hpi (n = 20 per
group). Enveloped RV particles averaged 112.736 ± 3.20
nanometers in diameter, and nonenveloped RV particles
averaged 72.391 ± 2.172 nanometers in diameter (statistically
significant P = 1.236E-34).

TEM morphometric analyses of MA104 cells.
Morphometric analyses using twelve TEM
micrographs of each treatment groups.
The
uninfected (NV-no virus), 20 µM A1 and 20 µM A3
only treated MA104 cells were compared to RV
infected cells as well as infected cells treated with A1
or A3 at 18 hpi. The three controls groups, no virus
(NV), 20 µM A1, and 20 µM A3 (Figure 4A, 4B and
4C, respectively) showed similar morphology.
Conversely, the RV-infected cells demonstrated an
increase in the size of the nucleus, many cytoplasmic
vesicles and cytoplasmic blebbing (Figure 4D)
which are characteristics of apoptosis (Elmore,
2007). However, RV-infected cells treated with A1
and A3 (Figures 4E and 4F, respectively) appeared
to have a more normal sized nucleus, and RVinfected cells treated with A1 had many
autophagosomes and large sized mitochondria-like
organelles (M), while the A3 treated cells exhibited

Fluorescent labelling of nucleus and plasma
membrane. MA104 cells treated with and without
arachidins with and without RV were collected at 18
hpi, fixed, and incubated with Alexa Fluor 594 wheat
germ agglutinin (WGA) and blue-fluorescent
Hoechst 33342 dye for selective staining of the
plasma membrane and nucleus, respectively. After
the cells were observed using the Olympus BX50
with DP Manager System compound light
microscope with epifluorescence, the pictures were
digitized and the pixels of the nucleus and whole cell
were measured using Macnification Version 2
(Orbicule, Inc., www.orbicule.com). Nucleus to
cytoplasm ratios were calculated and statistical
analyzed.
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Figure 4. Transmission electron micrograph (TEM) of Wa rotavirus (RV) infected MA104 cells at 18 hpi. A) NV, no virus; B)
A1 only; C) A3 only; D) RV only; E) RV+A1; F) RV+A3. Scale bars equal 1-3 microns. RV-infected cells (D) and RV+A3 (F) display
many cytoplasmic vesicles (V) while RV+A1 has many autophagic vesicles (AP) and large mitochondria-like organelles (M). RV+A3
has many vesicles (V) and small mitochondria-like organelles (sM).
Figure 5. TEM nucleus to cytoplasm ratios of MA104. Cells
were collected and processed for TEM analysis, and the areas
of the nucleus and cytoplasm of ten micrographs for each
treatment groups were measured with Macnification (Orbicule,
Inc.). Nucleus to cytoplasm ratios were calculated and
statistical analyses were performed. The data were analyzed by
one-way analysis of variance (ANOVA) and two-tailed
Student’s t tests (significance level, P < 0.05) with
Bonferroni's post hoc test to correct for multiple comparisons.
The data was graphed using a whisker and box plots. The box
represents all the data points within the lower (Q1) and upper
(Q3) quartiles with vertical lines with an x that represents the
median. The whiskers go from each quartile to the minimum
and maximum data points. Data points falling outside the
overall pattern of distribution were plotted as dots that represent
outliers. * RV was statistically different from RV+A1
(P=1.738E-05); RV+A3 (P=7.203E-06); NV (P=6.787E-06);
A1 (P=3.479E-06); and A3 (P=1.976E-06).
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the minimum and maximum data points. Data points falling
outside the overall pattern of distribution were plotted as dots
that represent outliers. *RV was statistically different from
RV+A1 (P=4E-22); RV+A3 (P=3.4E-20); NV (P=2.5E-21);
A1 (P=3E-18); and A3 (P=1.4E-17). **NV was statistically
different from A1 (P=1.4E-5); and ***NV was statistically
different from A3 (P=5.5E-5). ****NV was statistically
different from RV+A3 (P=0.0003).

Quantification of RV particles and size distribution
by TRPS analysis. TRPS analysis was performed on
the RV infected cell supernatants (with and without
treatments with A1 or A3) to display the
concentration of virus particles/mL, diameter of RV
particles and size distribution of particles. TRPS
allow for high-throughput single particle
measurements as virus particles are driven through
pores, one at a time, causing a blockade event that
can be measured for individual size; the number of
blockades is used to determine the concentration
(Vogel et al., 2011).

The RV only samples showed a concentration of 1.71
x 1013 particles/mL at 18 hpi, and the particles had a
dispersed range in diameter from approximately 60120 nm (Figure 7A). At the same time, RV-infected
cells treated with A3 showed a concentration of 4.25
x 1012 particles/mL with the particle size diameters
between 90-140 nm (Figure 7B). Additionally, RVinfected cells treated with A1 displayed a
concentration of 1.42 x 1012 particles/mL with a
population of particles between 70-150 nm (Figure
7C). This reveals a shift in the size distributions of
the populations of RV particles from a smaller size
that is more consistent with mature infectious RV
particles to larger, more immature RV particles with
the addition of the arachidins.
Western blot assays to detect rotavirus proteins.
Western blots were performed to visualize the
presence of RV nonstructural protein 4, NSP4 assays
as previously described (Parr and Ball, 2003; Parr et
al., 2006; Zhou, 2004) and the RV structural protein,
VP6, in RV-infected cell lysates with/without
treatment with arachidin 1(A1) or arachidin 3 (A3).
Rabbit polyclonal antiserum to the SA11 NSP4
synthetic peptide aa150-175 (αNSP4150-175) and
polyclonal antiserum to VP6 was kindly provided by
Dr. Judith Ball (Texas A&M Commerce, Commerce,
TX) and rabbit anti-GAPDH antibodies were
obtained from Thermo Fisher Scientific (Waltham,
MA). One microgram of the cell lysates was used
for NSP4, and 20 µg of cell lysates were used to
visualize VP6. Results showed a band at ~36 kDa
for GAPDH and ~42 kDa for VP6 (Figure 8A) and
displayed NSP4-specific bands ~28 and 56 kDa, and
a GAPDH-specific band ~36 kDa (Figure 8B).

Figure 6. Nucleus to cytoplasm ratios of whole MA104. Cells
were collected and fixed and stained with 5.0 µg/mL Alexa
Flour 594-labeled wheat germ agglutinin to observe membranes
and 1 µM Hoechst 33342 to visualize the nucleus. The
microscopic analyses of 45-56 cells from each treatment groups
were carried out using the Olympus BX50 microscope. The
images were digitalized and the pixels of the nucleus (N) and
whole cell were measured using Magnification Version 2
(Orbicule, Inc., www.orbicule.com). The N/Cytoplasm ratios
were analyzed by one-way analysis of variance (ANOVA) and
two-tailed Student’s t tests (significance level, P < 0.05) with
Bonferroni's post hoc test and graphed using a whisker and box
plots. The box represents all the data points within the lower
(Q1) and upper (Q3) quartiles with vertical lines with an x that
represents the median. The whiskers go from each quartile to
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Figure 7. TRPS analysis of arachidin treat MA104 cells. The size variations, virus concentrations and population distribution of
extracellular RV particles were measured from supernatants of RV-infected cells treated with/without A1 and A3 at 18 hpi. A) RVinfected supernatants, B) Supernatants from RV-infected cells treated with 20 µM A1, and C) Supernatants from RV-infected cells
treated with 20 µM A3

Figure 8B. The detection of the rotavirus nonstructural
protein NSP4 in MA104 cells. Cell lysates (1 µg) were
separated on a 12% SDS/PAGE gel, electroblotted onto a
nitrocellulose membrane. The membrane was probed
sequentially with a 1:1000 dilution of rabbit anti-NSP4 antisera
and a 1:5000 dilution (0.2ng/µl) of rabbit anti-GAPDH
antibody. Rabbit IgG HRP-linked whole donkey antibodies
were added at a 1:5000 dilution (0.2ng/µl), and the
chemiluminescent detection was performed using the
Prometheus Protein Biology Products ProSignal Femto ECL
Reagent (Genesee Scientific) and Amersham imager 600.
Results showed a band at ~36 kDa for GAPDH and ~28 and 56
kDa for NSP4.

Figure 8A. The detection of the rotavirus structural protein
VP6 in MA104 cells. Cell lysates (20 µg) were separated on a
12% SDS/PAGE gel, electroblotted onto a nitrocellulose
membrane, and probed sequentially with a 1:1000 dilution of
rabbit anti-VP6 antiserum and a 1:5000 dilution (0.2ng/µl) of
donkey anti-GAPDH antibody. Amersham Rabbit IgG, HRPlinked whole donkey antibodies were added at a 1:5000 dilution
(0.2ng/µl), and the chemiluminescent detection was performed
using the Prometheus Protein Biology Products ProSignal
Femto ECL Reagent (Genesee Scientific) and Amersham
imager 600. Results show a band at ~36 kDa for GAPDH and
~42 kDa for VP6.
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The presence of autophagy vesicles in rv infected
ma104 cells treated with A1 or A3. MA104 cells
from each treatment (n = 12 each) were scored
positive or negative for the presence of autophagic
vesicles as demonstrated in Figure 4E. Control cells
(no virus – NV) showed autophagosomes in 23.1%
of the observed cells, while 8.3% of the A3 alone
treated cells and 66.7% of the A1 alone treated cells
were positive for autophagic vesicles (Figure 9).

(Figure 10A lane 1 and 10B lane 1) and RV-infected
cell lysates (Figure 10A lane 2 and 10B lane 2) were
positive for both receptors, and there appears to be a
stronger signal with both CBR1 and CBR2
antibodies from the RV-infected cell lysates (Figure
8A lane 2 and 8B lane 2).

Figure 10. Cannabinoid Receptors 1 and 2 on MA104 cells.
Two-fold dilutions of MA104 cell lysates (10 µg, 5 µg, 2.5 µg,
1.25 µg) were added to nitrocellulose membranes [1-uninfected
and 2-RV (Wa)-infected], probed with a 1:1000 dilution (1
ng/µl) of rabbit anti-CBR1 (A) or anti-CBR-2 (B) antibodies
from Assay Biotechnology (Sunnyvale, CA) and reactive bands
were visualized by the addition and excitation of goat antirabbit antibodies with Alexa Fluor®546 (Life Technologies) at
a 1:5000 dilution (0.2ng/µl) using the Typhoon 9500 Plus laser
scanner.

Figure 9. Percent MA104 cells with autophagic vesicles at 18
hpi. TEMs of RV-infected, RV-infected arachidin treated, A1
only, A3 and NV (no virus) cells were scored positive or
negative for the presence of autophagic vesicles and the means
for each treatment (n = 12) were compared in a graphed format..

Comparatively, 5.9% of the RV-infected cells,
84.6% of RV-infected cells treated with A1, and
7.7% of RV-infected cells treated with A3 were
positive for autophagy vesicles (Figure 9).

DISCUSSION
A previous study in our laboratory has revealed that
A1 and A3 reduce the amount of progeny infectious
simian RV (SA11.4f) particles released from the
human intestinal cell line (HT29.f8), thus suggesting
a decrease in viral replication (Ball et al., 2015). This
study investigated changes in a human RV (Wa)infected African green monkey kidney cell line,
MA104, treated with either of the arachidins (A1 or

Immunoblot assays to detect cannabinoid receptors.
Immunoblot assays were performed to confirm the
presence of both A) cannabinoid receptor 1 (CBR1)
and B) cannabinoid receptor 2 (CBR2) on MA104
cells (Figure 10). Both uninfected cell lysates
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of extracellular particles among treatments with and
without arachidins, however the size distribution of
the particles varied significantly. It is notable that the
virus particles observed in the MA104 cells were
similar in size to the nanoparticles observed outside
the infected cells. This suggests that some of the
nanoparticles that are released from RV-infected
cells maybe infectious RV particles as these
supernatants produced more infectious RV particles
(~73nm) than the arachidin treated cells (~110nm) as
shown with the plaque forming assays. This suggests
that the maturation of the infectious RV particles is
affected with the addition of the arachidins (A1 and
A3). Previous studies infecting Caco-2 cells with
RRV (rhesus monkey rotavirus) have shown the
presence of extracellular vesicles (EVs) composed of
exosomes and apoptotic bodies obtained by
filtration/ultracentrifugation
or
differential
centrifugation (Barreto et al., 2010; Bautista et al.,
2015). A recent manuscript has reviewed data that
show Picornaviridae and Hepesviridae produce virus
particles in fully host-derived lipid bilayers that
resemble extracellular vesicles (EV), which are 50
nm–1 µm vesicles released by infected cells (van der
Grein et al., 2018). These studies indicate that some
of the nanoparticles that our study has measured
maybe EVs, therefore they will be further
characterized in future studies.
The nucleus to cytoplasm ratios studies and
plasma membrane blebbing of the RV-infected
MA104 cells showed characteristics of apoptosis
similar to that seen in previous studies
(Nikoletopoulou et al., 2013), while the appearance
of RV-infected cells treated with A1 or A3 was
similar to the control cells (NV, A1 and A3 only).
This implies cellular alterations to achieve
homeostasis.
Additionally, the increased presence of
autophagosomes in the MA104 cells with A1 alone
and RV with A1 suggested that A1 modulates
MA104 cellular homeostasis and RV infections by

A3) at 18hpi. Our hypothesis was that the human RV
(Wa) replication would be inhibited, and that the
ultrastructure of the MA104 cells would be affected
by the arachidins.
The viability assay verified that there were no
toxic effects on the MA104 cells treated with either
of the arachidins (A1 and A3), therefore 20µM
concentrations of A1 and A3 and 0.002% DMSO,
which was used to solubilize the arachidins, are
nontoxic to MA104 cells. It was interesting to
observe a significantly increased viability with the
addition of DMSO to the untreated cells when
compared to RV-infected cells treated with A1 or
A3. Although there were no significant differences
between RV-infected (no DMSO) and RV-infected
cells treated with A1 or A3, there was a significant
difference between RV-infected cells treated with
A1 and uninfected A3 treated cells, and significant
difference between RV-infected cells treated with
A1 and NV with DMSO. This infers a possible
difference in how A1 modifies an RV infection
versus noninfected MA104 cells treated with A1 or
DMSO alone.
Likewise, the decreased amount of infectious
RV produced in Wa-infected arachidin treated
MA104 cells resembled the decrease in progeny RV
produced in the simian RV, (SA11.4f)-infected
human intestinal cell line (HT29.f8) with arachidin
treatments (Ball et al., 2015). This indicated that A1
and A3 have antiviral properties that effect both
simian and human RV strains in both African green
monkey kidney (MA104) and human intestinal
(HT29.f8) cell lines.
TEM examination of intracellular RV particles
demonstrated two size populations; the more mature
nonenveloped (neRV) that are of similar sizes of
mature infectious RV particles and the less mature
enveloped (eRV) (Estes and Greenberg, 2013). At
the same time point (18hpi), TRPS analysis of
extracellular nanoparticles (50-150nm) using the
Izon qNano system revealed relatively equal number
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stimulating cells to utilize the autophagy pathway.
Autophagy is a conserved mechanism that is a
safeguard for cellular homeostasis. It produces
autophagosomes to degrade damaged proteins in the
cytoplasm and is believed to be a pro-survival
pathway (Noguchi and Hirata, 2015). However,
autophagy can be a form of programmed cell death
as demonstrated in a study that shows the activation
of cannabinoid receptors induces autophagy mediate
cell death through the stimulation of ER stress in
human glioma cells (Costa et al., 2016). Autophagy
is regulated by several cellular signaling pathways
including class I phosphoinositide 3-kinase (PI3K),
protein kinase B (PKB)-mammalian target of
rapamycin complex 1 (mTORC1), and other mTORindependent pathways (Chiu et al., 2014). The
consequences of the activation of the autophagy
depends on the types of cells and the stress-inducing
signals (Kenakin and Christopoulos, 2013; Raehal et
al., 2005; Rasmussen et al., 2011b, 2011a).
A recent drug screening study has identified the
PI3K/mTOR inhibitor, BEZ235, as a regulator of
both influenza virus production and cellular
metabolic homeostasis (Smallwood, et al, 2017).
Proteomic and functional analysis of the primary
epithelial cells show a regulation of homeostasis in
the infected cells that changes with the addition of
BEZ235. Also, BEZ235 protects mice challenged
with a lethal dose of influenza. This implies another
potential antiviral agent has similar effects on both
the virus and the cells. It will be interesting to
determine if A1, A3 and BEZ235 use similar
mechanism(s) of action.
Previously, a cannabinoid receptor binding
study has demonstrated that both A1 and A3 bind to
CBR1 and CBR2. Moreover, A3 was shown to be a
competitive receptor antagonist for CBR1, and A1
antagonized CBR1 agonists by both competitive and
non-competitive mechanisms (Brents et al., 2012).
Cannabinoid receptors (CBRs) are G-protein
coupled receptors (GPCRs) that are present on many

types of cells. They control diverse physiological
functions, including neural processes, cellular
metabolism, and modulation of cellular activity
including apoptosis (Bosier et al., 2010). The GPCRs
have been shown to activate different G proteins to
inhibit adenylyl cyclase, couple to the mitogenactivated protein kinase (MAPK) pathway, to couple
to phospholipase C causing the release of
intracellular calcium ([Ca]i), and activate
phosphatidylinositide-3-kinase
causing
the
inhibition of voltage-dependent calcium channels
(ICa)(Kamato et al., 2017; Khan et al., 2016; Neves
et al., 2002). The presence of CBRs on MA104 cells
suggests an activation of a receptor-mediated cell
signaling pathway(s) that could be used to modulate
an RV infection. This implies that the addition of A1
and A3 may initiate biased signaling, which is the
activation of different signaling pathways or the
same signaling pathways differently (Ibsen et al.,
2017). Biased signaling has been defined as the
model of how different ligands act on the same
GPCR, in the same tissue, can give rise to markedly
different cellular responses by stabilizing different
receptor conformations. The differential signaling
pathway activation by different agonists can also
arise as consequences of kinetics. Changes in the
timing of dissociation of different ligands may result
in receptor conformations that favor low affinity
interactions for a particular receptor/signaling
molecule pair to produce a signaling cascade (Ibsen
et al., 2017).
Also, some of the variability observed in the
pathways activating kinases downstream of both
CBR1 and CBR2 may be due to the differential
expression of the receptors on different cell types. An
example of this is presented in a study that shows the
requirement of high receptor expression for the
activation of pAkt, but the activation of ERK1/2 is
not affected by the level of expression of the
receptors (Cudaback et al., 2010). Future studies will
explain the influence of different cell types, with
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different receptor numbers and second messenger
expressions used in the cannabinoid receptor
signaling pathways. Biased signaling of GPCRdirected therapeutics would allow for a more targeted
approach for antiviral treatments.
In summary, this study showed that RVinfected MA104 cells treated with A1 or A3
exhibited a more normal ultrastructural appearance
than untreated RV-infected cells; a decrease in the
number of extracellular infectious RV particles; a
decrease in structural and nonstructural RV proteins;
and a shift to a larger size population of extracellular
nanoparticles. However, the fact that A1 produced
numerous autophagosomes while A3 did not, infers
that different mechanism(s) of action or different
stimulations of the same mechanism(s) of action
modulate an RV infection. This suggests that A1 and
A3 have anti-RV activity towards different RV
strains and implies potential broad range therapeutic
activity on other virus infections that employ similar
mechanism(s) of action. Future studies will resolve
these differences and disclose the mechanism(s) of
action of A1 and A3 that will illustrate their anti-RV
therapeutic activity.
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